Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

por Martinelli, M, Bonezzi, K, Riccardi, E, Kuhn, E, Frapolli, R, Zucchetti, M, Ryan, A J, Taraboletti, G, Giavazzi, R
Publicado 2007

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors

por Giordano, S., Morosi, L., Veglianese, P., Licandro, S. A., Frapolli, R., Zucchetti, M., Cappelletti, G., Falciola, L., Pifferi, V., Visentin, S., D’Incalci, M., Davoli, E.
Publicado 2016

IDN 5390: an oral taxane candidate for protracted treatment schedules

por Pratesi, G, Laccabue, D, Lanzi, C, Cassinelli, G, Supino, R, Zucchetti, M, Frapolli, R, D'Incalci, M, Bombardelli, E, Morazzoni, P, Riva, A, Zunino, F
Publicado 2003

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

por Colmegna, B, Uboldi, S, Frapolli, R, Licandro, S A, Panini, N, Galmarini, C M, Badri, Nadia, Spanswick, V J, Bingham, J P, Kiakos, Konstantinos, Erba, E, Hartley, J A, D'Incalci, M
Publicado 2015